Global Microbiome Therapeutics Market to Reach $19.1 Billion by 2030
The global market for Microbiome Therapeutics estimated at US$515.9 Million in the year 2022, is projected to reach a revised size of US$19.1 Billion by 2030, growing at a CAGR of 57% over the analysis period 2022-2030. C. Difficile Infection, one of the segments analyzed in the report, is projected to record 53.5% CAGR and reach US$6.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Obesity segment is readjusted to a revised 57% CAGR for the next 8-year period.The U.S. Market is Estimated at $170.2 Million, While China is Forecast to Grow at 53.8% CAGR
The Microbiome Therapeutics market in the U.S. is estimated at US$170.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 53.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50% and 47.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 37.9% CAGR.Select Competitors (Total 46 Featured) -
- 4D pharma plc
- AOBiome
- Enterome SA
- Evelo Biosciences, Inc.
- Ferring International
- Immuron Ltd.
- LNC Therapeutics
- Microbiome Therapeutics, LLC.
- Osel, Inc.
- OxThera AB
- Rebiotix, Inc.
- Ritter Pharmaceuticals, Inc.
- Second Genome
- Seres Therapeutics, Inc.
- Vedanta Biosciences, Inc.
- ViThera Pharmaceuticals, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D pharma plc
- AOBiome
- Enterome SA
- Evelo Biosciences, Inc.
- Ferring International
- Immuron Ltd.
- LNC Therapeutics
- Microbiome Therapeutics, LLC.
- Osel, Inc.
- OxThera AB
- Rebiotix, Inc.
- Ritter Pharmaceuticals, Inc.
- Second Genome
- Seres Therapeutics, Inc.
- Vedanta Biosciences, Inc.
- ViThera Pharmaceuticals, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 515.9 Million |
Forecasted Market Value ( USD | $ 19100 Million |
Compound Annual Growth Rate | 57.1% |
Regions Covered | Global |